KOTAI Biotechnologies

Executive Summary

KOTAI Biotechnologies is a Japanese private biotech company founded in 2016 and headquartered in Minoh, Osaka. It leverages an immune AI platform that combines artificial intelligence with immunology to model antibody structures, design antigens for vaccines, and analyze immune big data. The company's primary therapeutic focus is on infectious disease vaccines and immunological research. As a platform-stage company with 10-50 employees, KOTAI aims to accelerate drug discovery by providing AI-driven insights into antibody-antigen interactions. Despite limited public financial data and no disclosed funding rounds, the company has established a presence in the competitive immunology space, particularly through its unique integration of AI and immunology expertise. Its platform has the potential to streamline vaccine development and enable rapid response to emerging infectious threats.

Upcoming Catalysts (preview)

• Q3 2026Partnership with pharmaceutical company for AI-driven antibody discovery65% success
• Q4 2026Publication of platform validation study in peer-reviewed journal70% success
• Q2 2026Series A funding round announced60% success